您好,欢迎来到科研在线!科研采购 · 选型 · 实验方法
首页产品库品牌馆产品类别品牌新闻会议会展产品试用求职招聘资讯专题教程
REA / Bioactive Compounds

Human FcRn (FCGRT/b2M heterodimer) protein (C-His-Avi)

Human FcRn (FCGRT/b2M heterodimer) protein (C-His-Avi)

英诺赛图(InnoCyto)的 Human FcRn (FCGRT/b2M heterodimer) protein (C-His-Avi),属于生物活性物质,靶点/物种 FcRn(别名 FCGRT & B2M),表达宿主 CHO,C-His-Avi 标签,纯度 >95% based on SDS-PAGE under reducing condition,适用于酶联免疫(ELISA)。提供 25 μg、100 μg 规格,目录价 ¥983 起,仅供科研使用(RUO)。

科学仪器 供应商 上海英诺赛图 ↗ 型号 606301 更新 2026-11-12
参考价格区间
¥983
含税参考价,实际以配置与渠道报价为准
本条目供应商 上海英诺赛图原厂 1865个条目 进入企业主页

01产品图片

02产品简介

英诺赛图(InnoCyto)的 Human FcRn (FCGRT/b2M heterodimer) protein (C-His-Avi),属于生物活性物质,靶点/物种 FcRn(别名 FCGRT & B2M),表达宿主 CHO,C-His-Avi 标签,纯度 >95% based on SDS-PAGE under reducing condition,适用于酶联免疫(ELISA)。提供 25 μg、100 μg 规格,目录价 ¥983 起,仅供科研使用(RUO)。

03产品介绍

规格与货号

606301 | 25 μg | ¥983

606302 | 100 μg | ¥2,000

Product Details

Sources|Recombinant human Human FCGRT (Ala 24-Ser 297) with C-terminus His-Avi tag and Human b2M (Ile 21-MET119) with no tag are co-expressed in CHO cells.

Molecular Weight|Recombinant Human FCGRT has the predicted molecular weight of 33.99 kD. Recombinant Human b2M with no tag has the predicted molecular weight of 11.73 kD. Under DTT-reducing conditions, the proteins migrate at approximately 35 kD and 13 kD respecitively on SDS-PAGE.

Regulatory Status|RUO

Protein Concentration|25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.

Storage and Handling|Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ –70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.

Background Information

The neonatal Fc receptor (FcRn) is a critical component of the immune system that regulates the homeostasis and transport of immunoglobulin G (IgG) antibodies and albumin. Its primary function is to protect IgG and albumin from lysosomal degradation by binding to them in acidic intracellular compartments and recycling them back to the cell surface, where they are released at neutral pH. This mechanism extends the half-life of IgG and albumin in circulation, ensuring sustained immune protection and maintaining oncotic pressure in the blood.

Structurally, FcRn resembles a major histocompatibility complex (MHC) class I molecule. It is composed of a heavy α-chain (encoded by the FCGRT gene) non-covalently associated with β2-microglobulin. The α-chain forms three extracellular domains (α1, α2, and α3) and a transmembrane region. The binding sites for IgG and albumin are distinct: IgG interacts mainly through its Fc region with the α2-α3 interface of FcRn, whereas albumin binds to a separate site on the α1-α2 domains. Binding occurs optimally at endosomal pH (around 6.0) and is reversed at the physiological pH of blood (around 7.4).

The principal ligands of FcRn are IgG and serum albumin, but the receptor also interacts with IgG-based therapeutic antibodies and albumin-fused biologics. Through these interactions, FcRn plays a central role in pharmacokinetics by modulating antibody and drug half-lives. Variants or dysfunction of FcRn can influence immune responses and contribute to pathological conditions. For instance, altered FcRn expression or binding capacity may be involved in autoimmune diseases, such as myasthenia gravis or systemic lupus erythematosus, where excessive recycling of pathogenic autoantibodies exacerbates disease severity.

Therapeutically, the modulation of FcRn has become an emerging strategy. Blocking FcRn function can accelerate the degradation of pathogenic IgG in autoimmune disorders. FcRn inhibitors, such as efgartigimod and rozanolixizumab, have shown clinical efficacy by reducing IgG levels and improving disease symptoms. Conversely, enhancing FcRn interactions can prolong the half-life of therapeutic antibodies or albumin fusion proteins, thereby improving dosing efficiency. Consequently, FcRn represents an important pharmacological target in both antibody engineering and immune-mediated disease therapy.

Data Sheets

Purified Human FcRn / FCGRT (C-His-Avi) &b2M heterodimer protein (CHO expressed on SDS-PAGE under reducing (P+) and non-reducing (P-) conditions. The purity of the purified protein appears to be greater than 95% based on reducing condition.

规格明细:Storage and Handling — Briefly centrifuge the vial upon receipt. An unopened vial can be stored at 4°C for up to 2 weeks, or at -20°C or below for up to six months. The protein may be further diluted to 0.1 mg/mL using 0.22 µm-filtered PBS buffer (pH 7.4). For long-term storage, the diluted stock solution should be aliquoted and stored at ≤ –70°C to minimize freeze-thaw cycles. If additional dilution is required, carrier proteins such as FBS or BSA should be added to maintain protein stability.

04完整参数表

参数由厂商资料整理,采购前请以最终报价单与技术协议为准。

包装规格25 μg
ApplicationELISA, BLI
FormatLiquid, Purified
Expression HostCHO
Target NameFcRn, FCGRT & B2M
SpeciesHuman
Accession NumberXP_038512242.1 and NP_001271408.1
Affinity TagC-His-Avi
Purity>95% based on SDS-PAGE under reducing condition
Regulatory StatusRUO
Formulation1xPBS buffer, pH7.4, 0.22 µm filtered
Endotoxin levelNot tested
Protein Concentration25µg size is bottled at 0.2mg/mL concentration. 100 µg size is supplied at a lot-specific concentration.
目录价¥983

05荣誉与资质

该品牌暂未上传荣誉证书与资质文件。以下是平台可核验的公开信息,未上传项如实标注,不做推断。

  • 营业执照未上传
  • 品牌授权未上传
  • 产品检测报告未上传
会员身份
收费会员
经营身份
原厂
成立年份
2020 年
所在地
上海
收录条目
1865 个
平台核验
平台代管
向品牌方索取资质文件

06品牌与供应商

上海英诺赛图 原厂
InnoCyto

以可信赖的细胞研究试剂,助力科研突破

进入企业主页
1865 本目录条目
产地 / 总部上海市浦东新区
成立年份2020 年
本目录主营生化试剂 / 蛋白与抗体

InnoCyto(上海英诺赛图生物科技有限公司)致力于通过开发高质量细胞分析试剂,加速科学发现进程。公司为研究人员提供细胞层面探索所需的工具,推动免疫学、肿瘤学等多领域的研究创新。 核心团队拥有丰富的行业经验,曾参与全球头部生命科学公司的标杆项目搭建,深刻理解工业界与学术研究的前沿需求。试剂从设计之初即以精确性、一致性、高性能为核心标准,让科学家能把精力集中在最核心的研究工作上。 公司将深厚的科学积累与对品质的严格承诺相结合,力争成为全球研究人员信赖的合作伙伴。产品线覆盖经验证的一抗与二抗、同型对照、生物类似药抗体、重组蛋白、细胞因子、免疫检测试剂盒及配套试剂,并提供重组蛋白/抗体表达与标记偶联服务。

售后与服务

品牌资料由厂商公开信息与授权渠道核对整理;条目参数与价格以最终报价单为准。

引用此条目 产品目录 · 更新于 2026-11-12
科研在线(TeleVM). Human FcRn (FCGRT/b2M heterodimer) protein (C-His-Avi)(606301)[EB/OL]. 产品目录, 2026-11-12. https://www.suprotek.cn/products/item/human-fcrn-fcgrt-b2m-heterodimer-protein-c-his-avi-606301.html.
TeleVM. (2026, November 12). Human FcRn (FCGRT/b2M heterodimer) protein (C-His-Avi)(606301). 产品目录. https://www.suprotek.cn/products/item/human-fcrn-fcgrt-b2m-heterodimer-protein-c-his-avi-606301.html
@misc{biocsp_item_human_fcrn_fcgrt_b2m_heterodimer_protein_c_his_avi_606301,
  title        = {Human FcRn (FCGRT/b2M heterodimer) protein (C-His-Avi)(606301)},
  author       = {{科研在线}},
  year         = {2026},
  howpublished = {产品目录},
  note         = {更新于 2026-11-12,产品目录},
  url          = {https://www.suprotek.cn/products/item/human-fcrn-fcgrt-b2m-heterodimer-protein-c-his-avi-606301.html}
}

GB/T 7714 用于中文论文与报告;APA 7 用于英文期刊;BibTeX 可直接导入 Zotero、EndNote 或 LaTeX。

许可:CC BY-NC 4.0 · 转载注明来源
获取正式报价

Human FcRn (FCGRT/b2M heterodimer) protein (C-His-Avi)

提交后由平台转给品牌方,通常 1 个工作日内联系。不需要注册。